Empagliflozin and dapagliflozin have similar effectiveness on major adverse cardiac events (MACE) in type 2 diabetes patients with moderate cardiovascular risk
Current assessment
Synthesis pending
Confidence
Not assessed
Supporting evidence (0)
Nothing recorded on this side
Contradicting evidence (0)
Nothing recorded on this side
Discussion (0)
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.